← Back to patent-cliff list
Tibremciclib Tartrate
Tier C — Watch / tradeTibremciclib Tartrate
Betta Pharmaceuticals Co., Ltd.
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK6, CDK4
Indications (approved)：Breast cancer, Metastatic breast cancer
Regional status
US
-
EU
-
China
Approved
2025-06-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tibremciclib Tartrate?
Approved indications include: Breast cancer, Metastatic breast cancer.
When does the Tibremciclib Tartrate patent expire?
No public expiry year is available for Tibremciclib Tartrate yet; this page updates once verified.
How do I get a quote for Tibremciclib Tartrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01